On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
ACADEMIA
Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
Japan’s recent prostate cancer nod for the PARP inhibitor Lynparza (olaparib) is good news, but problems remain with the reimbursement of testing costs with FoundationOne CDx Cancer Genome Profile when it is used as a companion diagnostic (CDx), a professor…
To read the full story
ACADEMIA
- Japan Medical Societies Release Tavneos Discontinuation Guidance
November 6, 2026
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…